KR20230013016A - 아프리카 돼지 열병 바이러스 감염에 대한 백신 - Google Patents

아프리카 돼지 열병 바이러스 감염에 대한 백신 Download PDF

Info

Publication number
KR20230013016A
KR20230013016A KR1020227034852A KR20227034852A KR20230013016A KR 20230013016 A KR20230013016 A KR 20230013016A KR 1020227034852 A KR1020227034852 A KR 1020227034852A KR 20227034852 A KR20227034852 A KR 20227034852A KR 20230013016 A KR20230013016 A KR 20230013016A
Authority
KR
South Korea
Prior art keywords
leu
ile
asn
pro
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227034852A
Other languages
English (en)
Korean (ko)
Inventor
린다 딕슨
애너 레이스
사이먼 데이비스
위앤 젠크 루이
신지 이케미즈
Original Assignee
더 피르브라이트 인스티튜트
고꾸리쯔다이가꾸호오진 구마모또 다이가꾸
더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003292.6A external-priority patent/GB202003292D0/en
Priority claimed from GBGB2003289.2A external-priority patent/GB202003289D0/en
Priority claimed from GBGB2005880.6A external-priority patent/GB202005880D0/en
Priority claimed from GBGB2005878.0A external-priority patent/GB202005878D0/en
Priority claimed from GBGB2013541.4A external-priority patent/GB202013541D0/en
Application filed by 더 피르브라이트 인스티튜트, 고꾸리쯔다이가꾸호오진 구마모또 다이가꾸, 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 filed Critical 더 피르브라이트 인스티튜트
Publication of KR20230013016A publication Critical patent/KR20230013016A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020227034852A 2020-03-06 2021-03-05 아프리카 돼지 열병 바이러스 감염에 대한 백신 Pending KR20230013016A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB2003292.6 2020-03-06
GBGB2003292.6A GB202003292D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2003289.2A GB202003289D0 (en) 2020-03-06 2020-03-06 Vaccine
GB2003289.2 2020-03-06
GB2005880.6 2020-04-22
GB2005878.0 2020-04-22
GBGB2005880.6A GB202005880D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2005878.0A GB202005878D0 (en) 2020-04-22 2020-04-22 Vaccine
GB2013541.4 2020-08-28
GBGB2013541.4A GB202013541D0 (en) 2020-08-28 2020-08-28 Vaccine
PCT/GB2021/050560 WO2021176234A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Publications (1)

Publication Number Publication Date
KR20230013016A true KR20230013016A (ko) 2023-01-26

Family

ID=74870840

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227034852A Pending KR20230013016A (ko) 2020-03-06 2021-03-05 아프리카 돼지 열병 바이러스 감염에 대한 백신
KR1020227034853A Pending KR20230013017A (ko) 2020-03-06 2021-03-05 아프리카 돼지 열병 바이러스 감염에 대한 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227034853A Pending KR20230013017A (ko) 2020-03-06 2021-03-05 아프리카 돼지 열병 바이러스 감염에 대한 백신

Country Status (13)

Country Link
US (3) US20240293525A1 (https=)
EP (3) EP4114454A1 (https=)
JP (2) JP2023516713A (https=)
KR (2) KR20230013016A (https=)
CN (3) CN115397463A (https=)
AU (2) AU2021229654A1 (https=)
BR (2) BR112022016893A8 (https=)
CA (2) CA3170043A1 (https=)
CL (2) CL2022002412A1 (https=)
CO (2) CO2022014152A2 (https=)
MX (2) MX2022010373A (https=)
PH (2) PH12022552084A1 (https=)
WO (3) WO2021176235A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
CN120282794A (zh) * 2022-08-04 2025-07-08 T·马尔科姆 针对非洲猪瘟病毒的猪的预防和感染后治疗的显性负性抗原方法
WO2024057048A1 (en) * 2022-09-12 2024-03-21 Consejo Superior De Investigaciones Científicas Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110451A1 (en) * 2022-11-22 2024-05-30 Intervet International B.V. Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110453A1 (en) * 2022-11-22 2024-05-30 Gold Standard Diagnostics Madrid, S.A. Method for differentiating asfv infected from asfv vaccinated animals
CN117224669B (zh) * 2023-07-31 2024-07-30 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015091322A1 (en) * 2013-12-18 2015-06-25 Boehringer Ingelheim Vetmedica Gmbh Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
US9528094B2 (en) * 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Also Published As

Publication number Publication date
WO2021176234A1 (en) 2021-09-10
BR112022016891A2 (pt) 2023-01-24
BR112022016893A2 (pt) 2023-01-24
CA3170058A1 (en) 2021-09-10
CN116133680A (zh) 2023-05-16
BR112022016893A8 (pt) 2023-02-28
US20240293525A1 (en) 2024-09-05
EP4114453A1 (en) 2023-01-11
WO2021176235A1 (en) 2021-09-10
CN115397463A (zh) 2022-11-25
CO2022014256A2 (es) 2022-12-30
EP4114454A1 (en) 2023-01-11
EP4114455A1 (en) 2023-01-11
WO2021176236A1 (en) 2021-09-10
US20230124042A1 (en) 2023-04-20
MX2022010372A (es) 2023-01-19
KR20230013017A (ko) 2023-01-26
JP2023516713A (ja) 2023-04-20
AU2021229654A1 (en) 2022-11-03
CN115605223A (zh) 2023-01-13
CA3170043A1 (en) 2021-09-10
US20230117978A1 (en) 2023-04-20
PH12022552084A1 (en) 2024-02-26
CL2022002412A1 (es) 2023-03-03
JP2023516709A (ja) 2023-04-20
CL2022002416A1 (es) 2023-03-03
MX2022010373A (es) 2023-01-19
PH12022552086A1 (en) 2023-11-20
CO2022014152A2 (es) 2023-02-16
AU2021231402A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
RU2757933C2 (ru) Новые генно-инженерные вирусы осповакцины
KR20230013016A (ko) 아프리카 돼지 열병 바이러스 감염에 대한 백신
KR20210132002A (ko) 변형된 오르토폭스 바이러스 벡터
CN114555793B (zh) 基于基因i177l缺失的新型非洲猪瘟减毒活疫苗的开发
CN113215109B (zh) 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用
AU2017353868C1 (en) Synthetic chimeric poxviruses
KR20220031028A (ko) 아프리카 돼지 열병 백신
CN112899290B (zh) 一种天然免疫抑制基因缺失的减毒非洲猪瘟病毒株及应用
CN112543806A (zh) 合成嵌合痘苗病毒
CN116348135A (zh) 基于重组痘病毒的抗SARS-CoV-2病毒疫苗
JP2026041921A (ja) 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン
CN113151310B (zh) 非洲猪瘟基因缺失弱毒株的构建及其作为疫苗的应用
CN113025629A (zh) 一种基因缺失的减毒非洲猪瘟病毒株及应用
KR20220148823A (ko) 천연 또는 합성 dna에 의해 생산된 폭스바이러스-기반 벡터 및 그의 용도
CN115916803A (zh) 非洲猪瘟疫苗组合物
KR20200131863A (ko) 암 면역요법을 위한, 면역 관문 차단을 발현하는 종양용해 백시니아 바이러스
CN111107872A (zh) 有用于癌症免疫疗法的牛痘病毒突变体
KR20230136600A (ko) 안정적인 세포주에서 효율적인 성장을 가능하게 하는아프리카 돼지 열병 백신의 게놈 결실
KR20220082033A (ko) 레트로바이러스의 계내 생성을 위한 생산자 바이러스
RU2843901C1 (ru) Вакцина против инфекции вируса африканской чумы свиней
CN112261951A (zh) 包含合成嵌合痘苗病毒的干细胞及其使用方法
HK40078138A (en) Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
HK40076151B (zh) 基於基因i177l缺失的新型非洲猪瘟减毒活疫苗的开发
HK40076151A (en) Development of a novel live attenuated african swine fever vaccine based in the deletion of gene i177l
HK40042130A (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000